Abstract Number: 955 • 2015 ACR/ARHP Annual Meeting
Cancer Risk in 5,108 Patients with Juvenile Idiopathic Arthritis (JIA)
Background/Purpose: Given suspected links between inflammation and malignancy, several groups have attempted to elucidate the baseline risk of cancer in various inflammatory or autoimmune conditions, including rheumatoid arthritis,…Abstract Number: 956 • 2015 ACR/ARHP Annual Meeting
The Addition of One or More Biologics to Methotrexate in Children with Juvenile Idiopathic Arthritis Increases the Incidence of Infections and Other Adverse Events
Background/Purpose: Treatment of juvenile idiopathic arthritis (JIA) has greatly changed in the past 15 years thanks to the introduction of biologic agents but little is…Abstract Number: 957 • 2015 ACR/ARHP Annual Meeting
Double Blind Placebo Controlled Randomized Trial of Probiotics in Enthesitis-Related-Arthritis Category of JIA: Effect on Clinical and Immunological Parameters
Background/Purpose: Gut microflora influences the development and homeostasis of the immune system. Dysbiosis has been reported in various immuno-inflammatory diseases. Pathogenesis of enthesitis-related-arthritis (ERA) category…Abstract Number: 958 • 2015 ACR/ARHP Annual Meeting
The Time Spent in Inactive Disease before MTX Withdrawal Is Relevant with Regard to the Recurrence of Active Disease in Juvenile Idiopathic Arthritis (JIA) Patients
Background/Purpose: Methotrexate (MTX) is the most widely used disease modifying antirheumatic drug (DMARD) in JIA and regarded to be a safe drug, effective in around…Abstract Number: 959 • 2015 ACR/ARHP Annual Meeting
Results from the Childhood Arthritis and Rheumatology Research Alliance Systemic JIA Consensus Treatment Plans Pilot Study
Background/Purpose: Systemic JIA (sJIA) in usual practice is commonly treated with several agents, including glucocorticoids (GC), methotrexate (MTX) and biologic agents, most commonly IL1 or…Abstract Number: 960 • 2015 ACR/ARHP Annual Meeting
Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis Patients Previously Exposed to Biologics
Background/Purpose: Efficacy and safety of canakinumab (CAN) in systemic juvenile idiopathic arthritis (SJIA) have been demonstrated in two phase III trials.1 In these trials, over…Abstract Number: 961 • 2015 ACR/ARHP Annual Meeting
Altered Th Cell Plasticity Favors Th17 Cells in Rheumatoid Arthritis
Background/Purpose: Previously, T helper (Th) cell subsets have been regarded as irreversibly differentiated endpoints. However, evidence suggests that Th cell differentiation is a plastic process…Abstract Number: 962 • 2015 ACR/ARHP Annual Meeting
Profiling at the Single-Cell Level Reveals Evidence for Antigen-Driven Oligoclonal Expansion of Citrullinated Vimentin-Specific CD4+ T Cells in Peripheral Blood of Rheumatoid Arthritis (RA) Patients
Background/Purpose: RA is associated with shared epitope (SE)+ HLA-DRB1 alleles, including HLA-DRB1*0401, and development of anti-citrullinated protein autoantibodies. The preferential binding of citrullinated vimentin to…Abstract Number: 963 • 2015 ACR/ARHP Annual Meeting
Ectopic Lymphoid Tissue in the Lung Is Associated with Serum Rheumatoid Arthritis-Related Autoantibodies Even in Absence of Clinically Apparent Rheumatoid Arthritis
Background/Purpose: Lung disease has been associated with elevations of RA and Sjogren's-related autoantibodies (Abs), even in the absence of extrathoracic features of these diseases (Fischer…Abstract Number: 964 • 2015 ACR/ARHP Annual Meeting
Neutrophil Extracellular Traps Are Not Only Targets for ACPA-Positive IgG from Rheumatoid Arthritis Patients but Also Directly Trigger Pro- and Anti-Inflammatory Effects Partly Mediated By the C1q Complement Protein
Background/Purpose: Activated neutrophils (PMN) form neutrophil extracellular traps (NET). Those structures are expelled chromatin fibers composed of DNA and associated proteins. The process, NETosis, is…Abstract Number: 965 • 2015 ACR/ARHP Annual Meeting
Crystal Structure of Porphyromonas Gingivalis peptidylarginine Deiminase: Implications for Autoimmunity in Rheumatoid Arthritis
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are the main autoantibody system in rheumatoid arthritis (RA), and due to high sensitivity and specificity testing using the anti-CCP2…Abstract Number: 966 • 2015 ACR/ARHP Annual Meeting
In Rheumatoid Arthritis, Smoking Is Not Associated with Anti-Citrullinated Protein Antibodies per Se, but with the Concurrent Presence of Rheumatoid Factor, Anti-Citrullinated Protein Antibodies and Anti-Carbamylated Protein Antibodies
Background/Purpose : In rheumatoid arthritis (RA) a biological hypothesis has been proposed linking smoking with citrullination, the development of anti-citrulline autoimmunity and anti-citrullinated protein antibodies…Abstract Number: 967 • 2015 ACR/ARHP Annual Meeting
Safety, Tolerability, and Pharmacodynamics of ABT-122, a Dual TNF- and IL-17-Targeted Dual Variable Domain (DVD)-IgTM in Subjects with Rheumatoid Arthritis
Background/Purpose: TNF and IL-17 independently contribute to the pathophysiology of rheumatoid arthritis (RA) acting synergistically to induce mediators of inflammation and joint destruction. Selective dual…Abstract Number: 968 • 2015 ACR/ARHP Annual Meeting
Certolizumab Pegol in Combination with Methotrexate in DMARD-Naïve Patients with Active, Severe, Progressive Rheumatoid Arthritis: Results from a Randomized, Double-Blind, Controlled Phase 3 Study
Background/Purpose: Early stages of rheumatoid arthritis (RA) may provide a therapeutic window in which biologic agents are most effective.1 C-EARLY (NCT01519791) is a phase 3…Abstract Number: 969 • 2015 ACR/ARHP Annual Meeting
Namilumab, an Anti-Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Monoclonal Antibody: Results of the First Study in Patients with Mild-to-Moderate Rheumatoid Arthritis (RA)
Background/Purpose: GM-CSF mediates a range of immunological processes, such as stimulating the production of inflammatory mediators and differentiation of proinflammatory T-helper 17 cells, and may…
ACR Meeting Abstracts